14 Multiple Myeloma Clinical Trials in Aurora, IL (2026)

Q: How do I join a clinical trial in Aurora?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you.

Recruiting Multiple Myeloma Studies in Aurora

NCT07656584Recruiting

Implementation of Communication Disability Collection and Accommodations in Primary Care Settings

This multi-methods-multi-site study aims to adapt and evaluate the effects of an implementation support package of strategies to assist primary care clinics in documenting patients' communication disa...

Aurora, IL126,870 participantsNYU Langone Health

View Study Details

NCT05243797Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclista...

Aurora, IL1,594 participantsStichting European Myeloma Network

View Study Details

NCT05519085Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants...

Aurora, IL810 participantsCelgene

View Study Details

NCT06679101Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with T...

Aurora, IL520 participantsGlaxoSmithKline

View Study Details

NCT05786547Recruiting

V+PSF-M for Tobacco Cessation in HIV Care in India

The goal of this research study is to test an intervention to help quit tobacco use in participants with Human Immunodeficiency Virus (HIV). The study interventions used in this research study are: ...

Aurora, IL400 participantsUniversity of Colorado, Denver

View Study Details

NCT06455449Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease a...

Aurora, IL240 participantsAstraZeneca

View Study Details

NCT05650632Recruiting

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain,...

Aurora, IL210 participantsAbbVie

View Study Details

NCT05850234Recruiting

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma....

Aurora, IL182 participantsAstraZeneca

View Study Details

NCT07266441Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells c...

Aurora, IL157 participantsJanssen Research & Development, LLC

View Study Details

NCT06544499Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, el...

Aurora, IL69 participantsargenx

View Study Details

NCT06533098Recruiting

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT)....

Aurora, IL50 participantsJanssen Research & Development, LLC

View Study Details

NCT05722418Recruiting

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to deter...

Aurora, IL50 participantsCaribou Biosciences, Inc.

View Study Details

NCT06994845Recruiting

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetics (PK), safety and tolerability (including CV surveillance) of iptacopan in prim...

Aurora, IL31 participantsNovartis Pharmaceuticals

View Study Details

NCT05639907Recruiting

Miniscrew Stability and Peri-implant Inflammation When Precoated K21 vs Ethanol Control

To determine if coating miniscrews with K21 would increase the success rate of orthodontic miniscrews by reducing adjacent tissue inflammation....

Aurora, IL30 participantsUniversity of Colorado, Denver

View Study Details

About Multiple Myeloma Clinical Trials in Aurora

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 14 multiple myeloma clinical trials recruiting participants in Aurora, IL. These studies are seeking a combined 131,213 participants. Research is being sponsored by NYU Langone Health, Stichting European Myeloma Network, Celgene and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Aurora — FAQ

Are there multiple myeloma clinical trials in Aurora?

Yes, there are 14 multiple myeloma clinical trials currently recruiting in Aurora, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Aurora?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you about next steps.

Are clinical trials in Aurora free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Aurora studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 14 active trials in Aurora are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 13, 2026 from ClinicalTrials.gov